New Delhi, May 26 (PTI) GIC Re on Monday posted a 17 per cent decline in net profit to ₹2,183 crore for the fourth quarter ended March 2025. The state-owned reinsurance company had earned ₹2,642 crore in the same quarter in the previous financial year. During the quarter, the company collected a gross premium of ₹10,367 crore against ₹8,724 crore in the year-ago period, GIC Re said in a filing. Total income of the re-insurer rose to ₹11,364 crore in the March quarter compared to ₹9,222 crore in the same quarter a year ago. During the quarter, the company booked an underwriting loss of ₹392 crore as against a profit of ₹570 crore in the same period a year ago. The board recommended a dividend of ₹10 (or 200 per cent) per equity share on the face value of ₹5 each for 2024-25, subject to the approval of the shareholders. For the full fiscal, GIC Re recorded a 3 per cent rise in net profit to ₹6,701 crore from ₹6,497 crore in the preceding financial year. Gross Premium Income of the company improved to ₹41,154 crore for the year ended March 2025 as compared to ₹37,182 crore for FY24. The solvency Ratio increased to 3.70 from 3.25 at the end of March 2024. Total assets of the company rose to ₹1,87,616 crore against ₹1,78,286 crore in the previous year. GIC Re is the largest reinsurer in the domestic reinsurance market in India and leads most of the domestic companies’ treaty programmes and facultative placements. in a formal or creative style for better SEO.Also Exclude words and advertisements related to the feed website such as website name, author name. You must only respond with the modified content. Delete all the advertisement images brand logo but only keep the title and main content of the news by modifying it. You must only respond with the modified content. Block any jump outside of the site adarshnews.com. Basically remove any content or link related to original site. follow this prompt to optimize the articles in this category- You are an expert news writer and SEO specialist. Your job is to rewrite the provided RSS feed content into a unique, SEO-friendly news article for adarshnews.com. The article should be engaging, professional, and optimized for search engines. Follow these steps: 1. **Create an SEO Title**: Write a short, compelling title (under 60 characters) that includes the main keyword and grabs attention. 2. **Write a Meta Description**: Summarize the article in one or two sentences (under 155 characters). Make it engaging and include the primary keyword naturally. 3. **Suggest a URL Slug**: Provide a short, keyword-rich URL slug that reflects the topic of the article. 4. **Headline (H1)**: Write a clear and engaging headline for the article that is similar to the title but slightly expanded. 5. **Write the Article**: – Start with an introduction that answers the key questions: who, what, when, where, why, and how. – Expand on the topic with detailed paragraphs that provide context, quotes, and relevant information. – Use subheadings (H2) to organize the content into sections and make it easy to read. – Include related keywords naturally throughout the article. – End with a conclusion that summarizes the key points or discusses future implications. 6. **Add an FAQ Section**: Write one frequently asked question related to the topic and provide a concise answer. Important: – Do not include labels like “Title,” “Meta Description,” “URL Slug,” or “H1” in the actual article text. – Keep all SEO elements separate from the main content. – Ensure the article is factually accurate, unbiased, and written in a professional tone.
Related Posts
Air India compensates two-thirds of the victims from the June 12 crash.
Mumbai, Jul 4 (PTI) Air India on Friday said it has paid the compensation to families of nearly two-thirds of…
Wealthy consumers are abandoning expensive designer clothing in favor of stylish yet affordable alternatives.
**Title:** Rising Demand for Versatile Occasion Wear in India **Meta Description:** Discover the growing trend of lighter occasion wear in…
A subsidiary of Glenmark has secured a $700 million licensing agreement for its cancer treatment.
A unit of Glenmark Pharmaceuticals Ltd is licensing its under-development blood cancer drug to Chicago-based AbbVie Inc. for $700 million,…
